Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Public ClinicalTrials.gov record NCT07023835. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS
Study identification
- NCT ID
- NCT07023835
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Interventions
- 50 mg Usnoflast Drug
- 75 mg Usnoflast Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2025
- Primary completion
- Feb 29, 2028
- Completion
- Sep 30, 2028
- Last update posted
- Feb 4, 2026
2025 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Zydus US015 | La Jolla | California | 92037 | — |
| Zydus US008 | Orange | California | 92868 | — |
| Zydus US013 | San Francisco | California | 94109 | — |
| Zydus US005 | New Britain | Connecticut | 06053 | — |
| Zydus US012 | Tampa | Florida | 80045 | — |
| Zydus US007 | Atlanta | Georgia | 30322 | — |
| Zydus US010 | Boston | Massachusetts | 02114 | — |
| Zydus US006 | Detroit | Michigan | 48202 | — |
| Zydus US014 | Lincoln | Nebraska | 68510 | — |
| Zydus US003 | Winston-Salem | North Carolina | 27157 | — |
| Zydus 009 | Pittsburgh | Pennsylvania | 15212 | — |
| Zydus US001 | Dallas | Texas | 75206 | — |
| Zydus US002 | Houston | Texas | 77030 | — |
| Zydus US004 | Richmond | Virginia | 23298 | — |
| Zydus US011 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07023835, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07023835 live on ClinicalTrials.gov.